Pharmacy | Drug Updates | MIMS Malaysia

Malaysia
Search
Sign In

Pharmacy

Pharmacy

Home News Conferences Special Reports Multimedia

Product Highlight-Victoza

20180927000000

VICTOZA – Liraglutide 6 mg/mL soln for inj - Novo Nordisk

Product Highlight-Skycellflu

20180927000000

SKYCELLFLU – Inactivated quadrivalent influenza vaccine (inj) 0.5 mL - AJ Biologics

Original New Drug Application Approvals by US FDA (1 - 15 September 2018)

20180915000000

New drug applications approved by US FDA as of 1 - 15 September 2018 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (16 - 31 August 2018)

20180831000000

New drug applications approved by US FDA as of 16 - 31 August 2018 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (1 - 15 August 2018)

20180815000000

New drug applications approved by US FDA as of 01 - 15 August 2018 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (16 - 31 July 2018)

20180731230000

New drug applications approved by US FDA as of 16 - 31 July 2018 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (1 - 15 July 2018)

20180715000000

New drug applications approved by US FDA as of 1 - 15 July 2018 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (16 - 30 June 2018)

20180630000000

New drug applications approved by US FDA as of 16 - 30 June 2018 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (1 -15 June 2018)

20180615000000

New drug applications approved by US FDA as of 1 - 15 June 2018 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (16 - 31 May 2018)

20180531000000

New drug applications approved by US FDA as of 16 - 31 May which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!

NOAC better than VKA for elderly patients with atrial fibrillation

Stephen Padilla, 25 Jul 2019

Nonvitamin K antagonist oral anticoagulants (NOACs) appear to confer more clinical benefits to elderly patients with atrial fibrillation (AF) than vitamin K antagonist anticoagulants (VKAs), suggests a study, adding that this is primarily driven by the lower rates of major bleeding.

Diclofenac use may increase risk of major adverse cardiovascular events

Stephen Padilla, 11 Sep 2018

Use of diclofenac, a traditional nonsteroidal anti-inflammatory drug (NSAID) with cyclo-oxygenase-2 (COX-2) selectivity similar to COX-2 inhibitors, is associated with higher cardiovascular health risk compared with nonuse, paracetamol use and use of other traditional NSAIDs, a recent study has shown.